Collegium Pharmaceutical, Inc. (COLL) Market Cap & Valuation Ratios
Collegium Pharmaceutical, Inc. (COLL) has a market cap of $747.5M and a price-to-sales ratio of 0.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
COLLCollegium Pharmaceutical, Inc.Follow COLL — free
—
Price chart with a free account
- Market cap
- 747.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| COLL | 0.7 | — | 2.1 | 4.4 | — | +14% | 19% | 9% |
| PAHC | 1.6 | 15.9 | 1.5 | 9.1 | 0.6% | +17% | 13% | 14% |
| PCRX | 1.5 | 104.1 | 2.1 | 14.9 | 12.4% | +6% | 3% | 2% |
| ETON | 1.4 | — | 13.5 | 68.6 | 1.0% | +81% | 15% | 42% |
| CRON | 1.2 | 16.9 | 2.4 | 36.9 | 4.0% | +37% | -1% | -0.5% |
| AMPH | 1.1 | 14.9 | 1.9 | 8.1 | 14.3% | +1% | 16% | 8% |
| HROW | 1.1 | — | 4.6 | — | 0.5% | +21% | -1.0% | -2% |
| IRWD | 0.6 | 4.5 | 1.3 | 2.1 | — | +26% | 60% | — |
| AQST | 0.5 | — | 8.4 | — | -9.2% | +23% | -98% | — |
| EOLS | 0.5 | — | 1.8 | — | -4.7% | +14% | -6% | -26% |
| TLRY | 0.4 | — | 0.4 | — | — | +16% | -9% | -6% |
| Median of these 10 | 15.9 | 2.0 | 12.0 | 0.8% | +19% | 0.8% | 0.7% |
; EV/Sales 2.1 vs. 2.0.
Growth vs. price
each dot a company · hover or tap for valuesCOLL and ETON and HROW and AQST and EOLS and TLRY have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Collegium Pharmaceutical, Inc. — questions
- What is Collegium Pharmaceutical, Inc.'s market cap?
- $747.5M.
- What is Collegium Pharmaceutical, Inc.'s price-to-sales ratio?
- 0.9.
Every figure on this page comes from Collegium Pharmaceutical, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.